Cholesterol Heat Map Interactive
Visit the interactive map to learn more about cholesterol levels in high-risk CVD patients in your area. For more information, visit lipidlink.com.
AHA Scientific Sessions 2021
November 13–15, 2021, Virtual
Amgen is proud to be part of the American Heart Association Scientific Sessions 2021. While you're here, you can explore the latest scientific information and disease state education from Amgen, and learn about Amgen's long-term commitment to developing and delivering transformative medicines for patients with cardiovascular disease.
Cholesterol Learning Center
12:24
Podcast: Why It's Time to Reassess LDL‑C Goals in Your Patients with...
Learn how we can better manage cholesterol in high-risk patients and help reduce the risk of subsequent CV events.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: Sripal Bangalore, MD, MHA
1:04
The Role of PCSK9 in the Regulation of LDL Cholesterol
Overview of the mechanism of LDL-C regulation and the role of PCSK9.
DOWNLOAD BROCHURE4:12
How Have Cholesterol Guidelines Changed?
Watch how LDL-C levels recommended by multiple cholesterol guidelines have decreased over time and understand current recommendations for very high-risk patients.
ACC/AHA and ESC/EAS Guidelines One Pager
Download a quick guide to learn more about the 2018 ACC/AHA and 2019 ESC/EAS Cholesterol guidelines for identification of very high-risk patients and LDL-C recommendations.
59:04
Webinar: Guidelines, Discharge Protocol, and Routine Follow-up in Patients with Recent MI
Watch a webinar on guidelines, discharge protocol, and routine follow-up in patients with recent MI.
Speakers: Dominick J. Angiolillo, MD, PhD, FACC | Carl (Chip) Lavie, Jr, MD, FACC
Interactive Tool: Understanding Features of Plaque Vulnerability
See the progression of plaque from stable to vulnerable. Learn about the key features of plaque vulnerability.
LipidLink: An Amgen CV Website for Disease Education
Visit LipidLink.com to learn more about the science of atherosclerosis, the role of LDL-cholesterol, and opportunities to optimize clinical management of very high risk ASCVD patients.